Gilead Sciences Revenue vs. Current Valuation

GILD Stock  USD 92.58  0.17  0.18%   
Based on Gilead Sciences' profitability indicators, Gilead Sciences is performing exceptionally good at this time. It has a great odds to showcase excellent profitability results in December. Profitability indicators assess Gilead Sciences' ability to earn profits and add value for shareholders.
 
Total Revenue  
First Reported
1990-06-30
Previous Quarter
6.9 B
Current Value
7.5 B
Quarterly Volatility
2.9 B
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
At present, Gilead Sciences' Operating Cash Flow Sales Ratio is projected to increase slightly based on the last few years of reporting. At present, Gilead Sciences' Net Income From Continuing Ops is projected to decrease significantly based on the last few years of reporting. The current year's Change To Netincome is expected to grow to about 4.2 B, whereas Income Before Tax is forecasted to decline to about 4.2 B.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin1.070.7604
Significantly Up
Pretty Stable
For Gilead Sciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Gilead Sciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Gilead Sciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Gilead Sciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Gilead Sciences over time as well as its relative position and ranking within its peers.
  

Gilead Sciences' Revenue Breakdown by Earning Segment

Check out Risk vs Return Analysis.
For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.42)
Dividend Share
3.06
Earnings Share
0.09
Revenue Per Share
22.703
Quarterly Revenue Growth
0.07
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Gilead Sciences Current Valuation vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Gilead Sciences's current stock value. Our valuation model uses many indicators to compare Gilead Sciences value to that of its competitors to determine the firm's financial worth.
Gilead Sciences is rated as one of the top companies in revenue category among its peers. It also is rated as one of the top companies in current valuation category among its peers reporting about  4.92  of Current Valuation per Revenue. At present, Gilead Sciences' Total Revenue is projected to increase significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Gilead Sciences by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Gilead Revenue vs. Competition

Gilead Sciences is rated as one of the top companies in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 88.26 Billion. Gilead Sciences totals roughly 27.12 Billion in revenue claiming about 31% of equities under Health Care industry.

Gilead Current Valuation vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Gilead Sciences

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
27.12 B
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Gilead Sciences

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
133.38 B
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

Gilead Current Valuation vs Competition

Gilead Sciences is rated as one of the top companies in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 348.09 Billion. Gilead Sciences totals roughly 133.38 Billion in current valuation claiming about 38% of equities under Health Care industry.

Gilead Sciences Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Gilead Sciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Gilead Sciences will eventually generate negative long term returns. The profitability progress is the general direction of Gilead Sciences' change in net profit over the period of time. It can combine multiple indicators of Gilead Sciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income28 M37.6 M
Operating Income7.6 B4.4 B
Income Before Tax6.9 B4.2 B
Total Other Income Expense Net-746 M-708.7 M
Net Income5.6 BB
Income Tax Expense-1.2 B-1.2 B
Net Income Applicable To Common Shares5.3 B4.9 B
Net Income From Continuing Ops5.8 B6.6 B
Non Operating Income Net Other-522.9 M-496.8 M
Interest Income204.3 M194.1 M
Net Interest Income-918 M-963.9 M
Change To NetincomeB4.2 B
Net Income Per Share 4.54  4.77 
Income Quality 1.43  1.36 
Net Income Per E B T 0.83  0.94 

Gilead Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Gilead Sciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Gilead Sciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Gilead Sciences' important profitability drivers and their relationship over time.

Use Gilead Sciences in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Gilead Sciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Gilead Sciences will appreciate offsetting losses from the drop in the long position's value.

Gilead Sciences Pair Trading

Gilead Sciences Pair Trading Analysis

The ability to find closely correlated positions to Gilead Sciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Gilead Sciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Gilead Sciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Gilead Sciences to buy it.
The correlation of Gilead Sciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Gilead Sciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Gilead Sciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Gilead Sciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Gilead Sciences position

In addition to having Gilead Sciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Basic Utilities Thematic Idea Now

Basic Utilities
Basic Utilities Theme
Companies involved in production and distribution of electric, gas, water, and other energy utilities. The Basic Utilities theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Basic Utilities Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:
To fully project Gilead Sciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Gilead Sciences at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Gilead Sciences' income statement, its balance sheet, and the statement of cash flows.
Potential Gilead Sciences investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Gilead Sciences investors may work on each financial statement separately, they are all related. The changes in Gilead Sciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Gilead Sciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.